
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems Inc. is projecting a remarkable increase in total revenues, forecasting growth from $82.3 million in 2025 to $338.7 million by 2032, indicating a robust long-term growth trajectory. The company has demonstrated consistent quarterly growth in HEPZATO-related revenue since its launch, with a reported 37% quarter-over-quarter increase in the expected revenue for the HEPZATO KIT in the fourth quarter of 2024. Additionally, new site activations suggest a strong adoption of their product, supporting ongoing revenue growth and a promising pipeline leading into 2025.
Bears say
Delcath Systems Inc has faced significant challenges in terms of revenue growth and sustained profitability, reflecting broader concerns about the commercial viability of its Melphalan Hydrochloride for Injection product and its delivery system. The company's financial statements suggest increasing operational costs without a corresponding increase in sales, leading to persistent net losses that raise doubts about its ability to secure additional funding. Moreover, the market for oncology treatments is highly competitive and heavily regulated, which could further hinder Delcath's performance and its strategic positioning within the oncology sector.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares